Central administration of Dapagliflozin alleviates a hypothalamic neuroinflammatory signature and changing tubular lipid metabolism in type 2 diabetic nephropathy by upregulating MCPIP1
- Resource Type
- Article
- Source
- In
Biomedicine & Pharmacotherapy December 2023 168 - Subject
- Language
- ISSN
- 0753-3322